Horizon Therapeutics (HZNP) Tops Q3 EPS by 77c, Raises FY Revenue Guidance

Horizon Therapeutics (NASDAQ: HZNP) reported Q3 EPS of $1.74, $0.77 better than the analyst estimate of $0.97. Revenue for the quarter came in at $636.4 million versus the consensus estimate of $525.08 million.

GUIDANCE:

Horizon Therapeutics sees FY2020 revenue of $2.12-2.14 million, versus the consensus of $1.95 million.

• The Company now expects full-year 2020 net sales to range between $2.12 billion and $2.14 billion, an increase from the previous guidance range of $1.85 billion to $1.90 billion. The Company now expects TEPEZZA full-year 2020 net sales of greater than $800 million, compared to the previous guidance of greater than $650 million, and low double-digit KRYSTEXXA full-year 2020 net sales growth. Full-year 2020 adjusted EBITDA is now expected to range between $920 million and $940 million, an increase from the previous guidance range of $725 million to $775 million.

For earnings history and earnings-related data on Horizon Therapeutics (HZNP) click here.

You May Also Be Interested In

• Iridium Communications (IRDM) Reports In-Line Q1 EPS; offers outlook
• Badger Meter (BMI) Tops Q1 EPS by 17c ; Provides Outlook
• Elevance Health Inc. (ELV) Tops Q1 EPS by 16c, tops guidance